Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenesis Pens Drug Discovery Deal with Mitsubishi-Tokyo

NEW YORK, Aug 16 – NeoGenesis Drug Discovery has announced a deal to work with Mitsubishi-Tokyo Pharmaceuticals to identify small-molecule drug candidates. 

Under the terms of the deal, NeoGenesis of Cambridge, Mass., will use its genomics technologies to identify proteins that can be used as therapeutics. 

"Based on their previous record of success, we are confident that in a short period of time, NeoGenesis will be able to provide us with effective drug leads to the target we have supplied them with," Akihiro Tobe, president of Mitsubishi-Tokyo’s research and development division, said in a statement released Wednesday.

Mitsubishi-Tokyo Pharmaceuticals, Mitsubishi’s pharmaceutical division, will pay NeoGenesis for discovery in addition to milestones and royalties for products that result from the partnership. Mitsubishi-Tokyo did not disclose the target they are working on.

NeoGenesis has developed the Automated Ligand Identification System, which can screen 300,000 lead compounds a day to identify the compounds that bind with a protein target, according to the company. NeoGenesis has also created the neoMorph compound library, which contains over 10 million lead compounds. 

NeoGenesis’ other partnerships include deals with Biogen, Celltech, Merck, Microcide, and Oxford GlycoSciences. Earlier this month, NeoGenesis also announced a deal with Schering-Plough. The company has raised more than $54 million in private funding.


The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.